Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of efalizumab in combination with methotrexate in severe psoriasis
2007-001630-14Phase 4Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of efalizumab in plaque psoriasis and psoriasis (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Treatment safety (primary adverse event endpoint). Started Aug 2007; status: terminated.
02
Drugs
efalizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2007-001630-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001630-14.